中国麻风皮肤病杂志 ›› 2024, Vol. 40 ›› Issue (1): 26-30.doi: 10.12144/zgmfskin202401026

• 论著 • 上一篇    下一篇

阿达木单抗与司库奇尤单抗治疗甲银屑病的疗效及安全性比较

杜白音子,王惠平,罗素菊   

  1. 天津医科大学总医院皮肤性病科，天津，300052
  • 出版日期:2024-01-15 发布日期:2023-12-25

Efficacy and safety comparation of adalimumab and secukinumab in the treatment of nail psoriasis

DU Baiyinzi, WANG Huiping, LUO Suju   

  1. Department of Dermatology and Venereology, General Hospital of Tianjin Medical University, Tianjin 300052, China
  • Online:2024-01-15 Published:2023-12-25

PDF (PC)

135

摘要： 目的：比较司库奇尤单抗和阿达木单抗治疗甲银屑病的疗效和安全性。方法：回顾性分析在2020年1月至2023年3月就诊于天津医科大学总医院皮肤性病科确诊为甲银屑病并接受司库奇尤单抗或阿达木单抗治疗的患者，用药第0、4、12、24、36周后分别评价两组药物的疗效及安全性。计量资料两组间比较采用t检验，计数资料两组间比较采用Fisher精确检验，分析两组治疗前后甲银屑病严重程度指数（NAPSI）改善情况。结果：共收集36例患者，其中司库奇尤单抗治疗组17例，阿达木单抗治疗组19例。 司库奇尤单抗治疗组第 4、12、24、36周时 NAPSI 评分下降值和下降率分别为：7.60±4.34、13.20±4.09、17.60±3.79、21.20±4.87和(13.87±8.80)%、(24.13±9.44)%、(32.11±8.87)%、（38.41±9.64）%；阿达木单抗治疗组第4、12、24、36周时 NAPSI 评分下降值和下降率分别为：12.17±5.49、25.67±9.69、38.67±15.54、34.67±18.49和(20.19±7.20)%、(45.34±11.96)%、(62.64±18.59)%、（71.83±19.64）%。结论：司库奇尤单抗与阿达木单抗治疗甲银屑病第4周时，二者疗效相当；在治疗第12周时，阿达木单抗的疗效开始优于司库奇尤单抗；在治疗第24周时，阿达木单抗则明显更具治疗优势。

关键词: 甲银屑病, 生物制剂, 阿达木单抗, 司库奇尤单抗, 疗效评价

Abstract: Objective: To compare the efficacy and safety of secukinumab and adalimumab in the treatment of nail psoriasis. Methods: The patients with nail psoriasis and treated with secukinumab or adalimumab at the Department of Dermatology and Venereology of Tianjin Medical University General Hospital from January 2020 to March 2023 were retrospectively analyzed. The efficacy and safety of the two groups were evaluated after 0, 4, 12, 24 and 36 weeks of administration, respectively. The t test was used to compare the measurement data between the two groups, and the Fisher exact test was used to compare the count data between the two groups, to analyze the improvement of NAPSI before and after treatment in the two groups. Results: A total of 36 patients were collected, including 17 treated with secukinumab and 19 treated with adalimumab. The NAPSI score decreased by 7.60±4.34, 13.20±4.09, 17.60±3.79 and 21.20±4.87, and the decreasing rates of NAPSI score were (13.87±8.80)%, (24.13±9.44)%, (32.11±8.87)% and (38.41±9.64)% after 4, 12, 24 and 36 weeks in secukinumab treatment group. The NAPSI score decreased by 12.17±5.49, 25.67±9.69, 38.67±15.54, 34.67±18.49 and the decreasing rates of NAPSI score were (20.19±7.20)%, (45.34±11.96)%, (62.64±18.59)% and (71.83±19.64)% after 4, 12, 24 and 36 weeks in adalimumab treatment group. Conclusions: Secukinumab and adalimumab were equally effective in the treatment of nail psoriasis at week 4. At the 12th week of treatment, the efficacy of adalimumab began to be better than that of secukinumab. At the 24th week of treatment, adalimumab was significantly more advantageous.

Key words: nail psoriasis, biological agents, adalimumab, secukinumab, efficacy evaluation